Abiraterone (Zytiga) for hormone-naïve metastatic prostate cancer – first line
NIHR HSRIC
Record ID 32016000393
English
Authors' objectives:
Prostate cancer is usually a slowly growing cancer and may never cause any problems in some men. However, most men need treatment once it has spread to other parts of the body.
Abiraterone is a new drug for the treatment of prostate cancer for patients who have not yet received any other treatment. It is given as a tablet taken once daily. Some studies have suggested that abiraterone may work best in combination with two drugs that are already used for the treatment of prostate cancer, prednisolone and androgen deprivation therapy.
If abiraterone is licensed for use in the UK, it could be a new treatment option that may improve survival and the quality of life of men with prostate cancer.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/abiraterone-zytiga-for-hormone-naive-metastatic-prostate-cancer-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Abiraterone Acetate
- Androstenes
- Androstenols
- Male
- Prostatic Neoplasms
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.